Bristol-Myers beats profit estimates, thanks to strong Yervoy, Eliquis numbers

Bristol-Myers Squibb's ($BMY) melanoma drug Yervoy and clot-fighter Eliquis helped boost its earnings past analyst forecasts, with $333 million in profits on $3.9 billion in revenue. Compared with the same period last year, that's a decline in sales, but that's because Bristol-Myers sold out of its diabetes partnership with AstraZeneca ($AZN) later in the year. Report